A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)
Phase of Trial: Phase II
Latest Information Update: 30 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-782
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 12 Oct 2018 Planned initiation date changed from 16 Oct 2018 to 30 Oct 2018.
- 17 Sep 2018 New trial record